Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2000-08-18
2004-01-13
Wortman, Donna C. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S218100, C435S235100, C536S023720
Reexamination Certificate
active
06676936
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates, in general, to recombinant viable chimeric flaviviruses, and to vaccines for dengue virus and other flaviviruses, including tick-borne encephalitis virus (TBEV). The invention further relates to cDNA sequences encoding the RNA transcripts to direct the production of recombinant dengue type 4 virus, recombinant mutant dengue type 4 virus chimeric dengue viruses, chimeric dengue viruses incorporating mutations to recombinant DNA fragments generated therefrom, and the cells transformed therewith.
This invention further relates to vaccines produced from recombinant DNA. Specifically, this invention relates to vaccines for dengue virus encephalitis from recombinant DNA. The strategy used in this invention is also applicable to the development of subunit vaccines against other important flaviviruses such as Japanese B encephalitis virus, and the tick-borne encephalitis viruses for which routine vaccines are generally not available.
BACKGROUND INFORMATION
The family Flaviviridae includes approximately 60 enveloped, positive strand RNA viruses, most of which are transmitted by an insect vector. Many members of this family cause significant public health problems in different regions of the world (Monath, T. P. (1986) In: The Togaviridae and Flaviviridae. S. Schlesinger et al., eds. pp. 375-440. Plenum Press, New York). The genome of all flaviviruses sequenced thus far has the same gene order: 5′-C-preM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3′ in which the first three genes code for the structural proteins the capsid (C), the premembrane protein (pre M) and the envelope protein (E).
Dengue is a mosquito-borne viral disease which occurs in tropical and sub-tropical regions throughout the world. The dengue virus subgroup causes more human disease than any other member of the flavivirus family. Dengue is characterized by fever, rash, severe headache and joint pain. Its mortality rate is low. However, over the past few decades, a more severe form of dengue, characterized by hemorrhage and shock (dengue hemorrhagic fever/dengue shock syndrome; DHF/DSS) has been observed with increasing frequency in children and young adults. DHF/DSS occurs most often during dengue virus infection in individuals previously infected with another dengue virus serotype. This has led to the suggestion that immune enhancement of viral replication plays a role in the pathogenesis of the more severe form of disease (Halstead, S. B. (1988)
Science
239, 476-481).
Dengue epidemics are a major public health problem in many tropical and subtropical areas where the vector mosquito species are abundant. Despite 40 years of intensive research, safe and effective vaccines for dengue virus disease are not available. The WHO has assigned dengue virus as a high priority target for accelerated research and vaccine development.
Soon after their isolation in 1944, dengue viruses were passaged repeatedly in mouse brain, resulting in the selection of mouse neurovirulent mutants (Sabin, A. B. (1952)
Amer. J. Trop. Med. Hyg
. 1:30-50). Interestingly, studies performed in volunteers showed that mouse brain-adapted neurovirulent mutants of three strains of type 1 or type 2 dengue virus were attenuated, but still immunogenic for humans (Sabin, A. B. (1952)
Amer. J. Trop. Med. Hyg
. 1:30-50; Sabin, A. B. (1955)
Amer. J. Trop. Med. Hyg
. 4:198-207; Sabin, A. B. (1955)
Amer. J. Trop. Med. Hyg
. 4:198-207; Schlesinger, R. W. et al. (1956)
J. Immunol
. 77:352-364; Wisseman, C. L. et al. (1963)
Amer. J. Trop. Med
. 12:620-623). However, the mutants were not developed further as candidate vaccine strains because of concern for mouse brain antigens in the vaccine preparations. Since that time, virus mutants that: (i) exhibited the small plaque size phenotype, and/or (ii) were temperature sensitive, and/or (iii) were adapted to cell cultures derived from an unnatural host (i.e., host range mutants), have been selected and evaluated as candidates for inclusion in a live attenuated virus vaccine (Harrison, V. R. et al. (1977)
Infec. Immun
. 18:151-156; Hoke, C. H. et al. (1990)
Am. J. Trop. Med. Hyg
. 43:219-226; Bhamarapravati, N. et al. (1987) Bull.
WHO
. 65:189-195). However, despite 25 years of such efforts, safe, effective dengue vaccines are still not available for general use. Inactivated whole dengue virus vaccines have been shown to be insufficiently immunogenic. Live virus vaccines attenuated by serial passage in cell culture have suffered from genetic instability under attenuation or poor immunogenicity. The present invention represents a technical breakthrough by providing chimeric dengue and flavivirus vaccines.
These four serotypes of dengue viruses (type 1 to type 4) are distinguishable by plaque reduction neutralization using serotype-specific monoclonal antibodies and by less specific tests using polyclonal sera (Bankcroft, W. M. et al. (1979)
Pan Am. Hlth. Org. Sci. Publ
. 375:175-178; Henchal, E. A. et al. (1982)
Am. J. Trop. Med. Hyg
. 31:548-555). The existence of serotypes was first discovered during early studies in human volunteers, which showed that infection with one dengue serotype induced durable homotypic immunity, whereas heterotypic immunity lasted only 3 to 5 months (Sabin, A. B. (1 952)
Amer. J. Trop. Med. Hyg
. 1:30-50). An effective dengue vaccine that contains all four serotypes in order to induce broad immunity to dengue viruses in general would help to preclude the occurrence of DHF/DSS.
The complete nucleotide sequences have been determined for dengue virus types 3 and 4 and several strains of type 2 virus including the mouse-neurovirulent New Guinea C, however, only the 5′ portion of the type 1 virus genome has been sequenced (Mackow, E. et al. (1987)
Virology
159:217-228; Zhao, B. et al. (1986)
Virology
155:77-88; Osatomi, K. & Sumiyoshi, H. (1990)
Virology
176:643-647; Irie, A. et al. (1989)
Gene
75:197-211; Mason, P. W. et al. (1987)
Virology
161:262-267; Hahn, Y. S. et al. (1988)
Virology
162:167-180). The results of these studies indicate that the four dengue virus serotypes share a common genome organization. The genome of the dengue type 4 Caribbean strain 814669 was found to contain 10646 nucleotides (Mackow, E. et al. (1987)
Virology
159:217-228; Zhao, B. et al. (1986)
Virology
155:77-88). The first 101 nucleotides at the 5′ end and the last 384 at the 3′ end are non-coding. The remaining sequence codes for a 3386 amino-acid polyprotein which includes the three structural proteins, namely, capsid (C), premembrane (pre-M), and envelope (E), at its N-terminus, followed by seven non-structural proteins in the order, provided above, that is consistent with all Flavivirus genomes identified thus far. The polyprotein is processed to generate 11 or more viral proteins by cell signal peptidase(s) and by viral proteases (Markoff, L. (1989)
J. Virol
, 63:3345-3352; Falgout, B. et al. (1989)
J. Virol
, 63:1852-1860; Falgout, B. et al. (1991)
J. Virol
. 65:2467-2476; Hori, H. & Lai, C. J. (1990)
J. Virol
. 64:4573-4577).
Previously we constructed a full-length dengue virus cDNA that could serve as the template for transcription of infectious RNA. We have obtained stably cloned full-length dengue virus cDNA and in vitro RNA transcripts derived from the DNA template were shown to be infectious for cells in culture. However, this infectious construct and infectious RNA transcripts generated therefrom are pathogenic. Moreover, the attenuated dengue viruses generated thus far are genetically unstable and have the potential to revert back to a pathogenic form over time. Yet, attenuated viruses are desirable since they are generally known to provided long-lasting immunity. Therefore, modifications to this construct or to chimeric constructs that then direct the production of a less pathogenic virus would be a considerable advance to attenuated flavivirus vaccine technology. Accordingly, we have constructed a series of deletions in the 3′ non-coding region of cDNA, as disclosed herein, and have recov
Bray Michael
Chanock Robert M.
Eckels Kenneth H.
Lai Ching-Juh
Men Ruhe
Knobbe Martens Olson & Bear LLP
The United States of America as represented by the Department of
Wortman Donna C.
LandOfFree
Chimeric and/or growth-restricted flaviviruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric and/or growth-restricted flaviviruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric and/or growth-restricted flaviviruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3249139